Carl L.G. Hansen, Ph.D., born in May 1973, is the CEO and co-founder of AbCellera Biologics Inc., a Canadian biotechnology company that focuses on antibody therapeutics. He has a strong background in biochemistry, holding a Ph.D. from the University of...
Carl L.G. Hansen, Ph.D., born in May 1973, is the CEO and co-founder of AbCellera Biologics Inc., a Canadian biotechnology company that focuses on antibody therapeutics. He has a strong background in biochemistry, holding a Ph.D. from the University of British Columbia. Prior to his role at AbCellera, he co-founded another biotechnological venture, Precision NanoSystems, and served as a professor at UBC, contributing over 65 research manuscripts in microfluidics and genomics. Under his leadership, AbCellera has made significant strides in accelerating the development of antibody medicines. In 2023, his total compensation was reported at around $714,939, a drop from $8.8 million in 2022, which was largely due to fluctuations in company performance and stock values. Dr. Hansen's substantial insider ownership of approximately 20.59% of AbCellera highlights his commitment to the company's success. He’s been effectively at the helm since 2012, aiming to tackle complex challenges in the drug development process.